Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 17;14(2):e12398.
doi: 10.1002/pul2.12398. eCollection 2024 Apr.

Cardiopulmonary exercise testing and the 2022 definition of pulmonary hypertension

Affiliations

Cardiopulmonary exercise testing and the 2022 definition of pulmonary hypertension

Dirk Habedank et al. Pulm Circ. .

Erratum in

Abstract

Parameters of cardiopulmonary exercise testing significantly discriminate between healthy subjects and patients with pulmonary hypertension (PH), also according to the new 2022 definition of pulmonary hypertension (mean pulmonary arterial pressure mPAP > 20 mmHg). The cut-offs indicating on PH were peakVO2 ≤ 16.7 mL/min/kg (Youden-Index YI = 0.79), petCO2@AT ≤ 34 mmHg (YI = 0.67), and VE/VCO2@AT ≤ 30 (YI = 0.76).

Keywords: VE/VCO2@AT; cardiopulmonary exercise; peakVO2; petCO2@AT; pulmonary hypertension.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Above: petCO2@AT versus VE/VCO2@AT in healthy subjects (black), and in pulmonary hypertension patients according to the 2015 definition (orange) and additionally 2022 definition (blue). Below: Receiver operating characteristics of the three parameters with best discrimination between patients and healthy individuals. petCO2@AT, end‐tidal partial pressure of carbon dioxide at anaerobic threshold; peakVO2, maximum oxygen uptake per minute; VE/VCO2@AT, ventilation to carbon dioxide output ratio at anaerobic threshold.

References

    1. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano‐Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke‐Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S, Schwerzmann M, Dinh‐Xuan AT, Bush A, Abdelhamid M, Aboyans V, Arbustini E, Asteggiano R, Barberà JA, Beghetti M, Čelutkienė J, Cikes M, Condliffe R, de Man F, Falk V, Fauchier L, Gaine S, Galié N, Gin‐Sing W, Granton J, Grünig E, Hassoun PM, Hellemons M, Jaarsma T, Kjellström B, Klok FA, Konradi A, Koskinas KC, Kotecha D, Lang I, Lewis BS, Linhart A, Lip GYH, Løchen ML, Mathioudakis AG, Mindham R, Moledina S, Naeije R, Nielsen JC, Olschewski H, Opitz I, Petersen SE, Prescott E, Rakisheva A, Reis A, Ristić AD, Roche N, Rodrigues R, Selton‐Suty C, Souza R, Swift AJ, Touyz RM, Ulrich S, Wilkins MR, Wort SJ. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–3731. - PubMed
    1. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence‐based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018;138(9):861–870. - PMC - PubMed
    1. D'Alto M, Di Maio M, Romeo E, Argiento P, Blasi E, Di Vilio A, Rea G, D'Andrea A, Golino P, Naeije R. Echocardiographic probability of pulmonary hypertension: a validation study. Eur Respir J. 2022;60(2):2102548. - PubMed
    1. Arcasoy SM, Christie JD, Ferrari VA, Sutton MSJ, Zisman DA, Blumenthal NP, Pochettino A, Kotloff RM. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003;167(5):735–740. - PubMed
    1. Yasunobu Y, Oudiz RJ, Sun XG, Hansen JE, Wasserman K. End‐tidal pco2 abnormality and exercise limitation in patients with primary pulmonary hypertension. Chest. 2005;127(5):1637–1646. - PubMed